Technologies in the News

Magnus Medical Receives FDA Clearance for the SAINT Neuromodulation System for Non-Invasive, Individualized and Precise Treatment of Severe Depression

Research collaborations initiated with MUSC Foundation for Research Development, SU and the U of Pittsburgh to identify and advance therapies for genetic diseases and cancers.

Total of $195 million raised to date. | The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors.

The DiCE Molecules CEO is plotting a clinical trial launch for the biotech’s lead small molecule for psoriasis and wants to double the staff in the next year and a half.

IND clearance for Phase 1/2 trial establishes Graphite Bio as the first company advancing potentially curative sickle cell gene therapy to restore normal hemoglobin expression

Debanjan Ray apparently had big plans when he quietly left his long-held CFO spot at CytomX back in March 2019. He had gotten his own biotech.

Palleon Pharmaceuticals announced the completion of a $100 million Series B round to develop its pipeline of glyco-immunology therapies.

Next-generation gene editing company launched by Versant Ventures with additional backing by Samsara BioCapital

A Spanish health care company will buy out a Stanford University spinout focused on age-defying proteins from the clear, yellowish liquid portion of blood.

Researchers from Stanford Medicine and their collaborators aim to predict the onset of viral infection through data provided by wearable technology.